Johnson & Johnson (JNJ)

$259.10 -4.30 (-1.63%)
Market Cap 643.30B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 24.17
Forward PE 22.42
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 6,298,280
Avg Vol 8,208,874
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 79%
Beta 0.24
Analysts Strong Sell
Price Target $261.64

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Mountainmannn
Mountainmannn Jul. 9 at 9:23 PM
$ABUS $MRNA has to protect their Cancer delivery LPN line promised in negotiations during settlement for release on virus vaccines.. $PFE fighting to protect their ass and gain access to a new drug line. $JNJ just there messing with everyone's wallets because they can.. hahaha tables served let's eat!!
0 · Reply
parcha
parcha Jul. 9 at 8:57 PM
https://youtube.com/watch?v=3ua9yss0CA0&is=Sd_X_Kjy0CuJtJNW $JNJ
0 · Reply
MorganHoratio
MorganHoratio Jul. 9 at 7:23 PM
Best Robot Stocks 6. Medical and Surgical Robots $JNJ $SYK $SNN $ZBH $GMED While cloud-AI narratives swing, medical robotics stands out for defensive growth and tangible monetization. These tickers represent the infrastructure bedrock of automated healthcare. JNJ expands its MedTech moat as its soft-tissue robotic platform, OTTAVA, officially enters FDA review with stellar clinical data. SYK, the undisputed orthopedic titan, drives massive Mako expansions into shoulder procedures alongside its Mako RPS handheld system targeting surgery centers. Meanwhile, ZBH, SNN, and GMED secure high-margin clinical moats through ROSA, CORI, and ExcelsiusGPS platforms. Aging demographics deliver a structural mandate for hospital efficiency. Is surgical robotics the ultimate compounding play? Which asset holds the deepest moat: JNJ or SYK? Drop your positions below!
0 · Reply
SwingTradeMaestro
SwingTradeMaestro Jul. 9 at 5:36 PM
$JNJ $ABBV on sale for no reason. Yes please
0 · Reply
Wallstfan
Wallstfan Jul. 9 at 3:15 PM
$JNJ nice dip at $260 to add. We are headed to $280
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 9 at 2:39 PM
$ELTP $JNJ $PFE $GME I think PFE is making a deal.... Roaring kitty knowns something.
0 · Reply
2026TakeBackUSABegins
2026TakeBackUSABegins Jul. 9 at 2:09 PM
$DJT $ELTP $JNJ $MRNA $PFE Cool Embracing socialism One policy at a time
0 · Reply
VisionAlpha
VisionAlpha Jul. 9 at 2:00 PM
$ELTP $PFE $JNJ $MRNA $DJT Trump admin hasn’t rolled out anything direct for Elite yet, but the message is clear: bring generic drug manufacturing back to the U.S. That’s the kind of policy backdrop that can lift the whole pharma supply chain if it turns into action.
2 · Reply
DoubleUpwithChuck
DoubleUpwithChuck Jul. 9 at 1:57 PM
$ELTP $JNJ $MRNA $PFE Hakim cozies up to both sides. On the call last quarter he said he has enough meds for both sides; Painkillers for the DNC and antipsychotics for the GOP. 🤣🤣😂😁
0 · Reply
TraderDaKing
TraderDaKing Jul. 9 at 1:55 PM
$ELTP $PFE $JNJ $MRNA
0 · Reply
Latest News on JNJ
3 ‘Strong Buy’ Dividend Aristocrat Stocks, According to Top Analysts — July 9, 2026

2026-07-09T19:09:11.000Z - 2 hours ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks, According to Top Analysts — July 9, 2026

CTAS CVX

The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 4 hours ago

The Big 3: UNH, KO, JNJ

KO UNH

Johnson & Johnson announces FDA approval for THERMOCOOL SMARTTOUCH SF

2026-07-08T11:50:22.000Z - 1 day ago

Johnson & Johnson announces FDA approval for THERMOCOOL SMARTTOUCH SF

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 8, 2026, 7:45 AM EDT - 1 day ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Johnson & Johnson price target raised to $284 from $283 at Morgan Stanley

2026-07-08T11:40:29.000Z - 1 day ago

Johnson & Johnson price target raised to $284 from $283 at Morgan Stanley

Johnson & Johnson price target raised to $298 from $285 at Citi

2026-07-08T10:40:49.000Z - 1 day ago

Johnson & Johnson price target raised to $298 from $285 at Citi

Jim Cramer says these are the 5 stocks to buy during this market rotation

Jul 6, 2026, 6:29 PM EDT - 2 days ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Johnson & Johnson price target raised to $290 from $280 at HSBC

2026-07-06T14:25:32.000Z - 3 days ago

Johnson & Johnson price target raised to $290 from $280 at HSBC

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 13 days ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Johnson & Johnson presents new Imaavy data at EAN 2026 Congress

2026-06-26T16:40:11.000Z - 13 days ago

Johnson & Johnson presents new Imaavy data at EAN 2026 Congress

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 26, 2026, 12:35 PM EDT - 13 days ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Johnson & Johnson price target raised to $270 from $266 at Guggenheim

2026-06-26T12:36:03.000Z - 13 days ago

Johnson & Johnson price target raised to $270 from $266 at Guggenheim

Johnson & Johnson launches Dual Energy Thermocool Smarttouch in Europe

2026-06-25T09:10:22.000Z - 14 days ago

Johnson & Johnson launches Dual Energy Thermocool Smarttouch in Europe

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 25, 2026, 5:00 AM EDT - 14 days ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026

2026-06-16T20:26:11.000Z - 23 days ago

3 Strong Buy Dividend Aristocrat Stocks, According to Top Analysts — June 16, 2026

AMCR LOW

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 24 days ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:41 AM EDT - 26 days ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:33 AM EDT - 26 days ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:45 AM EDT - 4 weeks ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 4 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 11, 2026, 2:03 AM EDT - 4 weeks ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 11:22 AM EDT - 4 weeks ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 10, 2026, 6:20 AM EDT - 4 weeks ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 4 weeks ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 4 weeks ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 4 weeks ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 4 weeks ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 8, 2026, 8:00 AM EDT - 4 weeks ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 5, 2026, 6:24 PM EDT - 4 weeks ago

J&J beats lawsuit alleging that talc caused three women's cancer

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Jun 3, 2026, 12:04 AM EDT - 5 weeks ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

SLE

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jun 3, 2026, 12:03 AM EDT - 5 weeks ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

Jun 2, 2026, 6:24 PM EDT - 5 weeks ago

Jim Cramer says look to buy these 5 stocks outside the AI trade for diversification

JPM KMB MCD YUM

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

May 31, 2026, 8:39 AM EDT - 5 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

May 31, 2026, 8:29 AM EDT - 5 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

May 31, 2026, 8:27 AM EDT - 5 weeks ago

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

May 31, 2026, 8:01 AM EDT - 5 weeks ago

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

May 29, 2026, 2:00 PM EDT - 5 weeks ago

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

May 29, 2026, 8:18 AM EDT - 5 weeks ago

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

May 28, 2026, 7:10 PM EDT - 5 weeks ago

FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

May 28, 2026, 5:30 AM EDT - 6 weeks ago

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

May 27, 2026, 4:22 PM EDT - 6 weeks ago

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

May 27, 2026, 11:00 AM EDT - 6 weeks ago

Johnson & Johnson Transcript: Bernstein 42nd Annual Strategic Decisions Conference

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

May 21, 2026, 7:00 AM EDT - 7 weeks ago

Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi

Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 7 weeks ago

Johnson & Johnson says nipocalimab approved in China

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 11:30 AM EDT - 7 weeks ago

Johnson & Johnson Transcript: RBC Capital Markets Global Healthcare Conference 2026

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

May 19, 2026, 9:00 AM EDT - 7 weeks ago

Portal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences Leadership

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

May 14, 2026, 4:01 PM EDT - 2 months ago

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

STGW

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 2:20 PM EDT - 2 months ago

Johnson & Johnson Transcript: Bank of America Global Healthcare Conference 2026

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

May 12, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

May 11, 2026, 4:34 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

May 11, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

May 7, 2026, 11:34 AM EDT - 2 months ago

This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J

MO

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

May 7, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 2 months ago

CVS to drop J&J's Stelara from its main formularies

CVS

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

May 5, 2026, 8:05 AM EDT - 2 months ago

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

May 5, 2026, 8:05 AM EDT - 2 months ago

Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

May 5, 2026, 7:00 AM EDT - 2 months ago

Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

May 4, 2026, 8:00 AM EDT - 2 months ago

CAPLYTA® (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

May 2, 2026, 4:00 AM EDT - 2 months ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Apr 30, 2026, 8:02 AM EDT - 2 months ago

Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

Why These 3 Forever Stocks Belong on Your Watchlist

Apr 28, 2026, 11:10 AM EDT - 2 months ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

Apr 27, 2026, 4:33 PM EDT - 2 months ago

Johnson & Johnson to Participate in the Bernstein's 42nd Annual Strategic Decisions Conference

J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 2 months ago

J&J sees AI halving the time to generate drug development leads

Mountainmannn
Mountainmannn Jul. 9 at 9:23 PM
$ABUS $MRNA has to protect their Cancer delivery LPN line promised in negotiations during settlement for release on virus vaccines.. $PFE fighting to protect their ass and gain access to a new drug line. $JNJ just there messing with everyone's wallets because they can.. hahaha tables served let's eat!!
0 · Reply
parcha
parcha Jul. 9 at 8:57 PM
https://youtube.com/watch?v=3ua9yss0CA0&is=Sd_X_Kjy0CuJtJNW $JNJ
0 · Reply
MorganHoratio
MorganHoratio Jul. 9 at 7:23 PM
Best Robot Stocks 6. Medical and Surgical Robots $JNJ $SYK $SNN $ZBH $GMED While cloud-AI narratives swing, medical robotics stands out for defensive growth and tangible monetization. These tickers represent the infrastructure bedrock of automated healthcare. JNJ expands its MedTech moat as its soft-tissue robotic platform, OTTAVA, officially enters FDA review with stellar clinical data. SYK, the undisputed orthopedic titan, drives massive Mako expansions into shoulder procedures alongside its Mako RPS handheld system targeting surgery centers. Meanwhile, ZBH, SNN, and GMED secure high-margin clinical moats through ROSA, CORI, and ExcelsiusGPS platforms. Aging demographics deliver a structural mandate for hospital efficiency. Is surgical robotics the ultimate compounding play? Which asset holds the deepest moat: JNJ or SYK? Drop your positions below!
0 · Reply
SwingTradeMaestro
SwingTradeMaestro Jul. 9 at 5:36 PM
$JNJ $ABBV on sale for no reason. Yes please
0 · Reply
Wallstfan
Wallstfan Jul. 9 at 3:15 PM
$JNJ nice dip at $260 to add. We are headed to $280
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 9 at 2:39 PM
$ELTP $JNJ $PFE $GME I think PFE is making a deal.... Roaring kitty knowns something.
0 · Reply
2026TakeBackUSABegins
2026TakeBackUSABegins Jul. 9 at 2:09 PM
$DJT $ELTP $JNJ $MRNA $PFE Cool Embracing socialism One policy at a time
0 · Reply
VisionAlpha
VisionAlpha Jul. 9 at 2:00 PM
$ELTP $PFE $JNJ $MRNA $DJT Trump admin hasn’t rolled out anything direct for Elite yet, but the message is clear: bring generic drug manufacturing back to the U.S. That’s the kind of policy backdrop that can lift the whole pharma supply chain if it turns into action.
2 · Reply
DoubleUpwithChuck
DoubleUpwithChuck Jul. 9 at 1:57 PM
$ELTP $JNJ $MRNA $PFE Hakim cozies up to both sides. On the call last quarter he said he has enough meds for both sides; Painkillers for the DNC and antipsychotics for the GOP. 🤣🤣😂😁
0 · Reply
TraderDaKing
TraderDaKing Jul. 9 at 1:55 PM
$ELTP $PFE $JNJ $MRNA
0 · Reply
TraderDaKing
TraderDaKing Jul. 9 at 1:37 PM
$ELTP $PFE $JNJ $MRNA $DJT President Donald Trump’s administration has not yet announced direct, company-specific programs to help Elite Pharmaceuticals. However, the administration is actively pushing to move generic drug manufacturing back to the U.S., and is securing historic pricing deals with other major pharmaceutical companies. Also Nassart Hakim is a member at Trumps golf club in New Jersey and is rumored to be a close ally of the President.
0 · Reply
TraderDaKing
TraderDaKing Jul. 9 at 1:18 PM
$JNJ $PFE $MRNA Who is the New Partner? This is going to run today.
1 · Reply
grampslol
grampslol Jul. 9 at 12:43 PM
poor $MNKD pumper @clan ... smh ... delusional cultist chumping the gullible about nadaburger furoscizzle and it's ability to get the afizzle company out of pennyworld... a sad 🤡 ... #pumperslie $PFE $BX $JNJ
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 9 at 12:33 PM
$ELTP $BAC $TSLA $TRUMP.X $BAC $JNJ Say hello to the new MEME stock of the biotech world. ELTP. Elite is ready to go dig news coming an in 2027 the BIGGEST news in drugs will be known around the world from this company........
1 · Reply
clan
clan Jul. 9 at 12:29 PM
$MNKD $JNJ $PFE $BX Mannkind's revenue growth projections for its upcoming FDA-approved Furoscix Ready•Flow Autoinjector have evolved from analysts' conservative projections originally derived last year during scPharma market valuations being made. #milestones #buyout #undervalued Up and to the right.
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 9 at 12:27 PM
$ELTP $PFE $MRNA $JNJ BIG DEALS COMING. FDA Filings: Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product was submitted for an anticoagulant. Elite Pharmaceuticals has recently introduced several new products, including the commercial launch of methadone hydrochloride tablets and a generic version of Vyvanse® (lisdexamfetamine dimesylate). Additionally, the company received FDA approval for generic Requip XL® and has filed an Abbreviated New Drug Application (ANDA) with the U.S. FDA for a generic anticoagulant. WE ARE THE CHAMPIONS Elite. ELTP too the Moon.
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jul. 9 at 11:06 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
SparkyReturns
SparkyReturns Jul. 9 at 3:20 AM
$ICU This isn't good for any of us investing in biotech - or the patients, who could be anyone here or their family. Just sayin'. $SLS $JNJ $MCK
5 · Reply
AStrokeOfLuck
AStrokeOfLuck Jul. 8 at 9:15 PM
$AMGN $PFE $SPY $XBI $JNJ
0 · Reply
TalkMarkets
TalkMarkets Jul. 8 at 8:16 PM
#Dividend Kings In Focus - #JohnsonJohnson $JNJ $MSFT https://talkmarkets.com/article/dividend-kings-in-focus---johnson-johnson-1783541681
0 · Reply
DoubleUpwithChuck
DoubleUpwithChuck Jul. 8 at 3:45 PM
$ELTP it is low. I think people think Oatsc stocks don’t file financials on time. $ELTP has never not filed on time. They are very consistent. $LLY $TEVA $JNJ
1 · Reply
GeniusintheFlesh
GeniusintheFlesh Jul. 8 at 3:40 PM
$ELTP $PFE $JNJ $MRNA $GME ELTP is an Epstein-Trump pe do supporter stock? That is highly disappointing. Don't get suckered by this, the pe do prez just cashed billions in crypto from his supporters. Don't become another one of this adjucated ra pists victims!
0 · Reply